Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tirasemtiv

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Tirasemtiv: Sponsors, patents, clinical trial progress

Tirasemtiv is an investigational drug.

There have been 7 clinical trials for Tirasemtiv. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Amyotrophic Lateral Sclerosis, Sclerosis, and Motor Neuron Disease. The leading clinical trial sponsors are Cytokinetics, National Institute of Neurological Disorders and Stroke (NINDS), and [disabled in preview].

There are seven US patents protecting this investigational drug and seventy-two international patents.

Recent Clinical Trials for Tirasemtiv
A Study for Patients Who Completed VITALITY-ALS (CY 4031)CytokineticsPhase 3
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a YearCytokineticsPhase 3
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)CytokineticsPhase 2

See all Tirasemtiv clinical trials

Clinical Trial Summary for Tirasemtiv

Top disease conditions for Tirasemtiv
Top clinical trial sponsors for Tirasemtiv

See all Tirasemtiv clinical trials

US Patents for Tirasemtiv

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tirasemtiv   Start Trial Combination ALS therapy Cytokinetics, Inc. (South San Francisco, CA)   Start Trial
Tirasemtiv   Start Trial Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use Cytokinetics, Inc. (South San Francisco, CA)   Start Trial
Tirasemtiv   Start Trial Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use Cytokinetics, Inc. (South San Francisco, CA)   Start Trial
Tirasemtiv   Start Trial Modulating skeletal muscle Cytokinetics, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tirasemtiv

Drugname Country Document Number Estimated Expiration Related US Patent
Tirasemtiv Australia 2012281042 2031-07-13   Start Trial
Tirasemtiv Australia 2016244263 2031-07-13   Start Trial
Tirasemtiv Brazil 112014000742 2031-07-13   Start Trial
Tirasemtiv Canada 2849213 2031-07-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.